<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296045</url>
  </required_header>
  <id_info>
    <org_study_id>CG1142</org_study_id>
    <nct_id>NCT04296045</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of MCE on Glucose and Insulin Responses in Healthy Males</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Cross-over Study, to Investigate the Effect of Mazie Cob Extract on Post-prandial Glucose and Insulin Responses in Healthy Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge Glycoscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlantia Food Clinical Trials</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge Glycoscience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maize Cob Extract (MCE) is intended to be used as a bulking agent in food. The purpose of&#xD;
      this study is to determine the glycaemic and insulinemic response of MCE consumed in&#xD;
      isolation compared to glucose; the glycaemic and insulinemic response will also be determined&#xD;
      for MCE alone and in combination with glucose. This is a randomised, double-blind,&#xD;
      single-centre trial in 10 healthy male participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2020</start_date>
  <completion_date type="Actual">August 28, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in venous glucose from incremental area under the curve (iAUC) (T-15 to T120 minutes)</measure>
    <time_frame>Through intervention periods of two hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in venous insulin from incremental area under the curve (iAUC) (T-15 to T120 minutes)</measure>
    <time_frame>Through intervention periods of two hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal concentrations for glucose and insulin (Cmax)</measure>
    <time_frame>Through intervention periods of two hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Dysglycemia</condition>
  <arm_group>
    <arm_group_label>Glucose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MCE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MCE + Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MCE</intervention_name>
    <description>MCE</description>
    <arm_group_label>MCE</arm_group_label>
    <arm_group_label>MCE + Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>Glucose</description>
    <arm_group_label>Glucose</arm_group_label>
    <arm_group_label>MCE + Glucose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be able to give written informed consent;&#xD;
&#xD;
          -  Be between 18 and 60 years of age inclusive;&#xD;
&#xD;
          -  Have a body mass index &lt;30 Kg/m2;&#xD;
&#xD;
          -  Have a fasting glucose level of â‰¤6.0 mmol/L&#xD;
&#xD;
          -  Be in general good health, as determined by the investigator;&#xD;
&#xD;
          -  Be willing to fast for at least 10 hours before the study visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of any of the following criteria will exclude the participant from&#xD;
             participating in the study:&#xD;
&#xD;
          -  Are less than 18 or greater than 60 years of age;&#xD;
&#xD;
          -  Recent gastroenteritis or food borne illness such as confirmed food poisoning within&#xD;
             the past 4 weeks;&#xD;
&#xD;
          -  Have taken a medication or dietary supplement that may influence GI activity within&#xD;
             the 2-weeks prior to screening;&#xD;
&#xD;
          -  Have a history of abdominal surgery (excluding appendectomy);&#xD;
&#xD;
          -  Have taken anaesthesia within the past 4 weeks;&#xD;
&#xD;
          -  Have taken antibiotics within the past 12-weeks;&#xD;
&#xD;
          -  Have a recent history of drug and/or alcohol abuse at the time of enrolment;&#xD;
&#xD;
          -  Are a smoker (defined as &gt;5 cigarettes/week);&#xD;
&#xD;
          -  Have made any major dietary change in the past 3 months;&#xD;
&#xD;
          -  Have planned major changes in lifestyle (i.e. diet, dieting, exercise level,&#xD;
             travelling) during the duration of the study;&#xD;
&#xD;
          -  Have an active gastrointestinal disorder or previous gastrointestinal surgery;&#xD;
&#xD;
          -  Have irritable bowel syndrome, diagnosed or undiagnosed and treated with chronic&#xD;
             medications;&#xD;
&#xD;
          -  Have a metabolic or endocrine disorder such as diabetes, thyroidism, or other&#xD;
             metabolic disorder;&#xD;
&#xD;
          -  Have a severe chronic disease i.e. cancer, renal failure, hepatitis, HIV, cirrhosis&#xD;
             etc., or with a history of such diseases;&#xD;
&#xD;
          -  Have a gastrointestinal disease i.e., chronic diarrhoea, Crohn's disease, ulcerative&#xD;
             colitis, diverticulosis, stomach or duodenal ulcers, or with a history of such&#xD;
             diseases;&#xD;
&#xD;
          -  Are severely immunocompromised (HIV positive, transplant patient, on antirejection&#xD;
             medications, on a systemic steroid for &gt;30 days, or chemotherapy or radiotherapy&#xD;
             within the last year);&#xD;
&#xD;
          -  Experiences alarm features such as weight loss, rectal bleeding, recent change in&#xD;
             bowel habit (&lt;3 months) or abdominal pain;&#xD;
&#xD;
          -  Participants who, in the opinion of the investigator, are considered to be poor&#xD;
             attendees or unlikely for any reason to be able to comply with the trial;&#xD;
&#xD;
          -  Participant is currently receiving treatment involving experimental drugs. If the&#xD;
             participant has been in a recent experimental trial, these must have been completed&#xD;
             not less than 30 days prior to this study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Nicholson, M.Phil; M.Sc</last_name>
    <role>Study Director</role>
    <affiliation>Cambridge Glycoscience</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Dinan, M.D; Ph.D; D.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlantia Food Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlantia Food Clinical Trials</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

